Bone health in hypogonadal men

Irwig, Michael S.

doi:10.1097/mou.0000000000000104

Cited by 17 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, testosterone replacement in hypogonadal men improved bone mass and strength. 86 Testosterone improved muscle mass and function in older adults (aged 60–65 years), as well as young adults (aged 19–35 years): 87 results are not suggested as being sex-specific. 88 Moreover, positive effects of testosterone on muscle strength have been reported in community-dwelling frail older adults (aged ⩾65 years), 89 as well as healthy community dwelling older adults (aged ⩾60 years).…”

Section: Pharmacological Management Of Osteosarcopeniamentioning

confidence: 95%

Therapeutic approaches to osteosarcopenia: insights for the clinician

Fatima

Brennan-Olsen

Duque

2019

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Osteopenia/osteoporosis and sarcopenia are both age-related conditions. Given the well-defined bone and muscle interaction, when osteopenia and sarcopenia occur simultaneously, this geriatric syndrome is defined as ‘osteosarcopenia’. Evidence exists about therapeutic interventions common to both bone and muscle, which could thereby be effective in treating osteosarcopenia. In addition, there are roles for common nonpharmacological strategies such as nutritional intervention and physical exercise prescription in the management of this condition. In this review we summarize the evidence on current and upcoming therapeutic approaches to osteosarcopenia.

show abstract

Section: Pharmacological Management Of Osteosarcopeniamentioning

confidence: 95%

Therapeutic approaches to osteosarcopenia: insights for the clinician

Fatima

Brennan-Olsen

Duque

2019

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…It is still unclear whether or not opioid-induced hypogonadism is associated with an increased risk of bone fractures. 45 Few available data come from studies on addicts receiving methadone maintenance treatment (MMT). The first report by Pedrazzoni et al 46 showed that among male chronic heroin users, the more recent the last dose, the more likely a low BMD.…”

Section: The Second Possible Connection: Reduced Bone Densitymentioning

confidence: 99%

The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism

Coluzzi¹,

Pergolizzi²,

Raffa³

et al. 2015

TCRM

View full text Add to dashboard Cite

The current literature describes the possible risks for bone fracture in chronic analgesics users. There are three main hypotheses that could explain the increased risk of fracture associated with central analgesics, such as opioids: 1) the increased risk of falls caused by central nervous system effects, including sedation and dizziness; 2) reduced bone mass density caused by the direct opioid effect on osteoblasts; and 3) chronic opioid-induced hypogonadism. The impact of opioids varies by sex and among the type of opioid used (less, for example, for tapentadol and buprenorphine). Opioid-associated androgen deficiency is correlated with an increased risk of osteoporosis; thus, despite that standards have not been established for monitoring and treating opioid-induced hypogonadism or hypoadrenalism, all patients chronically taking opioids (particularly at doses ≥100 mg morphine daily) should be monitored for the early detection of hormonal impairment and low bone mass density.

show abstract

“…Male hypogonadism due to testosterone deficiency is common in men aged 40‐79 years, approximately 20% of whom are suffering from the disease, and incidence increases with age . Several studies show that hypogonadism can lead to arteriosclerosis, decreased bone mineral density and depressed mood as well as fatigue and sexual dysfunction . Testosterone replacement therapy (TRT) is capable of exerting some positive effects, such as improvement of muscle mass and sexual function; however, long‐term use of testosterone can also bring about a variety of side effects .…”

Section: Introductionmentioning

confidence: 99%

Leydig‐like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats

Hua

Liu

Zhou

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

| 3971 wileyonlinelibrary.com/journal/jcmm | INTRODUC TI ONMale hypogonadism due to testosterone deficiency is common in men aged 40-79 years, approximately 20% of whom are suffering from the disease, and incidence increases with age. 1,2 Several studies show that hypogonadism can lead to arteriosclerosis, decreased bone mineral density and depressed mood as well as fatigue and sexual dysfunction. [3][4][5] Testosterone replacement therapy (TRT) is AbstractIn the past few years, Leydig cell (LC) transplantation has been regarded as an effective strategy for providing physiological patterns of testosterone in vivo. Recently, we have successfully converted human foreskin fibroblasts (HFFs) into functional Leydig-like cells (iLCs) in vitro by using the CRISPR/dCas9 system, which shows promising potential for seed cells. However, it is not known whether the reprogrammed iLCs can survive or restore serum testosterone levels in vivo. Therefore, in this study, we evaluate whether reprogrammed iLCs can restore the serum testosterone levels of castrated rats when they are transplanted into the fibrous capsule. We first developed the castrated Sprague Dawley rat model through bilateral orchiectomy and subsequently injected extracellular matrix gel containing transplanted cells into the fibrous capsule of castrated rats. Finally, we evaluated dynamic serum levels of testosterone and luteinizing hormone (LH) in castrated rats, the survival of implanted iLCs, and the expression levels of Leydig steroidogenic enzymes by immunofluorescence staining and Western blotting. Our results demonstrated that implanted iLCs could partially restore the serum testosterone level of castrated rats, weakly mimic the role of adult Leydig cells in the hypothalamic-pituitary-gonadal axis for a short period, and survive and secrete testosterone, through 6 weeks after transplantation.Therefore, this study may be valuable for treating male hypogonadism in the future. K E Y W O R D SCRISPR/dCas9, human fibroblasts, Leydig-like cells, male hypogonadism, reprogramming, target gene activation

show abstract

Bone health in hypogonadal men

Cited by 17 publications

References 22 publications

Therapeutic approaches to osteosarcopenia: insights for the clinician

Therapeutic approaches to osteosarcopenia: insights for the clinician

The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism

Leydig‐like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats

Contact Info

Product

Resources

About

Bone health in hypogonadal men

Cited by 17 publications

References 22 publications

Therapeutic approaches to osteosarcopenia: insights for the clinician

Therapeutic approaches to osteosarcopenia: insights for the clinician

The unsolved case of &ldquo;bone-impairing analgesics&rdquo;: the endocrine effects of opioids on bone metabolism

Leydig‐like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats

Contact Info

Product

Resources

About

The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism